Wachtlin Joachim, Ringwald Andreas, Maulhardt Tobias, Pohl Karin, Wiedon Annette
Augenabteilung Sankt-Gertrauden Krankenhaus, Paretzer Strasse 12, 10713, Berlin, Germany.
Augenklinik Klinikum Dortmund, Beurhausstraße 40, 44137, Dortmund, Germany.
Graefes Arch Clin Exp Ophthalmol. 2016 Aug;254(8):1529-1536. doi: 10.1007/s00417-015-3242-5. Epub 2015 Dec 17.
In the non-interventional ophthalmological study 'BRIDGE' the routine care of patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab was observed in Germany. A patient regularly sees the general ophthalmologist (GO) for monitoring and, if needed, the injecting ophthalmologist (IO) for intravitreal injections (IVI). Thus, patients are routinely treated by two ophthalmologists in parallel and patient care depends on their collaboration. This cooperation was evaluated based on network questionnaires.
'BRIDGE' was a multicenter, national, open-label, prospective, observational study, conducted between July 2010 and December 2012. The network questionnaire for GOs consisted of 51 questions, while the similar questionnaire for IOs consisted of 43 questions, addressing the type and details of the individual collaboration. The statistical analysis was purely descriptive.
The network questionnaire for GOs was completed by 152 GOs, regularly cooperating with 2.5 ± 1.1 IOs, while the questionnaire for IOs was completed by 43 IOs, regularly cooperating with 23.2 ± 23.6 GOs. Generally, both GOs and IOs stated that they regularly exchange information regarding the patients' situation. Diagnostic standards were only established for 15 % of the GOs' collaborations and for 35 % of the IOs' collaborations. After initial treatment, both GOs and IOs agreed on the medical significance of regular monitoring visits performed by the GOs. Agreements on re-treatment criteria were only established in the case of 16 % of the GOs and 28 % of the IOs. Overall, both GOs and IOs were satisfied with the current situation, with regard to the medical treatment situation for patients and to the cooperation within the networks.
The network questionnaires revealed well-established cooperation between IOs and GOs in Germany with an accepted division of responsibilities for the routine care of patients with nAMD. However, the cooperation between two ophthalmologists treating one patient harbors risks. Agreements on diagnostic and re-treatment criteria would help to improve network performance and outcomes.
在非干预性眼科研究“BRIDGE”中,观察了德国接受雷珠单抗治疗的新生血管性年龄相关性黄斑变性(nAMD)患者的常规护理情况。患者定期去普通眼科医生(GO)处进行监测,如有需要,则去注射眼科医生(IO)处进行玻璃体内注射(IVI)。因此,患者通常由两位眼科医生并行治疗,患者护理取决于他们之间的协作。基于网络问卷对这种合作进行了评估。
“BRIDGE”是一项多中心、全国性、开放标签、前瞻性观察研究,于2010年7月至2012年12月进行。GO的网络问卷包含51个问题,而IO的类似问卷包含43个问题,涉及个体协作的类型和细节。统计分析纯属描述性分析。
152名GO完成了针对GO的网络问卷,他们与2.5±1.1名IO定期合作;43名IO完成了针对IO的问卷,他们与23.2±23.6名GO定期合作。总体而言,GO和IO均表示他们会定期就患者情况交换信息。仅15%的GO协作以及35%的IO协作建立了诊断标准。初始治疗后,GO和IO对于GO进行定期监测访视的医学意义达成了一致。仅16%的GO和28%的IO就再治疗标准达成了一致。总体而言,GO和IO对当前情况感到满意,包括患者的医疗状况以及网络内的合作情况。
网络问卷显示德国的IO和GO之间建立了良好的合作关系,对于nAMD患者的常规护理职责分工得到认可。然而,两位眼科医生共同治疗一名患者的合作存在风险。就诊断和再治疗标准达成一致将有助于提高网络绩效和治疗效果。